Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar

Orthogonal Assessment of Biotherapeutic Glycosylation: A Case Study Correlating N-Glycan Core Afucosylation of Herceptin with Mechanism of Action

(2016) Rosie Upton et al.   ANALYTICAL CHEMISTRY

A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects

(2016) Xavier Pivot et al.   CLINICAL THERAPEUTICS

Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines

(2015) Silvia Boero et al.   Journal of Translational Medicine

Drift, Evolution, and Divergence in Biologics and Biosimilars Manufacturing

(2014) Sundar Ramanan et al.   BIODRUGS

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients

(2013) Branka Petricevic et al.   Journal of Translational Medicine

Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans

(2012) Marcella Yu et al.   mAbs

Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer

(2012) Thuy Vu et al.   Frontiers in Oncology

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

(2011) Martin Schiestl et al.   NATURE BIOTECHNOLOGY

Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer

(2010) Teemu T. Junttila et al.   CANCER RESEARCH

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood

(2009) Shigeru Iida et al.   BMC CANCER

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

(2008) M. Peipp et al.   BLOOD

Terminal sugars of Fc glycans influence antibody effector functions of IgGs

(2008) T Shantha Raju   CURRENT OPINION IN IMMUNOLOGY

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY